Cervical cancer : Screening and treatmentof pre-cancerous lesionsfor secondary preventionof cervical cancer. Technology landscape

Titre:      Cervical cancer : Screening and treatmentof pre-cancerous lesionsfor secondary preventionof cervical cancer. Technology landscape
Catégorie:      Cancer cervical, Gynécologie, Santé de la femme, Document
LivreID:      138
Auteurs:      UNITAID
ISBN-10(13):      000-00-0-000000-0
Date de publication:      2019
Number of pages:      46
Langue:      Anglais
Classification:      1 
Image:      cover
Livre électronique:      Télécharger 1.pdf

In support of the WHO 2030 goal toward the elimination of cervical cancer as a public
health problem, Unitaid seeks to accelerate access and scale use of optimal tools for
cervical cancer secondary prevention in low- and middle-income countries. The objective
of this landscape is to provide an overview of technologies for secondary prevention of
cervical cancer, particularly for screening, diagnosis, and treatment at the critical stage
of intervention for pre-cancerous lesions. This landscape identifies some of the critical
technology and access barriers for managing the disease at the pre-cancer stage, as well
as points toward opportunities to reduce the impact of cervical cancer in low and middleincome
countries (LMICs).
Strategies that identify women at risk of cervical cancer and provide them early detection
and treatment at the pre-cancer stage have dramatically decreased incidence and mortality
of cervical cancer in several high-income countries. There is an urgent need for a paradigm
shift in screening for cervical cancer in many LMICs in order to achieve broader impact
through equitable access to early detection and treatment of pre-cancer. Women living
with HIV are particularly vulnerable, with HPV co-infection progressing more frequently and
rapidly to cervical cancer. Even as countries introduce the HPV vaccine, access to efficient
screen-and-treat programmes will remain key for several decades to reach unvaccinated
vulnerable women and to identify cases in the vaccinated cohorts.
A number of technologies are available on the market that are recommended as costeffective
and may therefore be considered in priority interventions for LMICs. However,
tools, such as HPV molecular tests and alternative treatment devices, are out of reach for
most populations in need, with access barriers on both the supply and demand sides of the
markets for these technologies. Such barriers mean that healthcare workers in LMICs rely on
the use of substandard tools and strategies for management of pre-cancer and prevention
of cervical cancer and cervical cancer-related mortality. In addition, market shaping is
needed to improve the affordability and availability of high-quality screen-and-treat tests
and other medical devices. Promising new screening technologies need a pathway for
development along with a process for national regulatory approval across regions, with
an effective deployment strategy in combination with market-shaping interventions to
increase availability and affordability.
Unitaid supports the advancement of innovative cervical cancer screening and treatment
tools to enable a paradigm shift in screening and treatment programmes in LMICs, by 1)
catalyzing markets for cervical cancer screening and treatment by addressing access
barriers for the most promising new technologies; and 2) supporting introduction of these
products in selected early-adopter countries through effective delivery channels.

Please past text to modal